#United States #San Diego #biopharmaceuticals #Regulus Therapeutics #Healthcare Conferences

Regulus Therapeutics to Attend December Healthcare Investment Conferences

Regulus Therapeutics Inc. (NASDAQ: RGLS), a prominent biopharmaceutical entity based in San Diego, is set to unveil its latest advancements in medicine focusing on microRNAs at several key investor conferences in early December 2024. These events present a unique opportunity for investors to gain insights into Regulus' innovative pipeline and preclinical programs.

Upcoming Events

The company will take part in the Evercore 7th Annual HealthCONx Conference, hosting a fireside chat on Tuesday, December 3, 2024, at 3:50 PM ET. Following this, Regulus will showcase its portfolio during a presentation at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024, at 11:10 AM ET.

Investors and interested stakeholders can access these presentations live through the Events and Presentations section of Regulus' investor relations website. Furthermore, recordings will be available for replay for 90 days post-event.

About Regulus Therapeutics

Regulus Therapeutics focuses on developing groundbreaking medicines that target microRNAs, a type of small RNA molecule that plays a critical role in regulating gene expression. Leveraging its expertise in oligonucleotide drug discovery and a robust intellectual property portfolio, Regulus is at the forefront of biopharmaceutical innovation. Their headquarters is situated in San Diego, California, a hub for biotech enterprises.

Forward-Looking Statements

In line with its expertise, Regulus Therapeutics emphasizes that certain statements included in recent press releases may be deemed forward-looking statements. These statements, which concern future events or results, are inherently subject to risks and uncertainties. The company's ambitions regarding the RGLS8429 program and its preclinical pipeline are contingent on various factors that may evolve over time.

Some identified risks that could impact performance include:

• - The innovative approach taken by Regulus in developing new drugs may not lead to successful marketable products.
• - The substantial effort required to navigate regulatory mechanisms and obtain FDA approvals.
• - Possible unsuccessful results from ongoing preclinical and clinical studies which could hinder progress.

Through these conferences, Regulus Therapeutics aims to present not only their current undertakings but also their vision for the future, fostering engagement with the investment community while addressing pertinent inquiries related to their therapies.

As the healthcare landscape continues to evolve, the insights gleaned from these discussions will be invaluable for investors and stakeholders eager to understand the future trajectory of Regulus Therapeutics. Ensure to mark your calendars for these pivotal events in December, which could greatly influence the understanding of the innovative pathways being pursued within the biopharmaceutical sector.